ASX:LTR
ASX:LTRMetals and Mining

Major Equity Raise Might Change the Case for Investing in Liontown Resources (ASX:LTR)

In early August 2025, Liontown Resources completed a follow-on equity offering totaling A$316 million, issuing over 432 million new ordinary shares at A$0.73 per share, following earlier filings to raise additional funds via direct listing and other placements. The scale of these equity raisings is significant, as it alters Liontown's capital structure and could influence both funding flexibility and shareholder dilution. We'll explore how this major capital raise and influx of new shares...
NasdaqGS:SNDX
NasdaqGS:SNDXBiotechs

Syndax Pharmaceuticals (SNDX) Is Up 26.1% After FDA Priority Review for Revuforj and Revenue Surge

Syndax Pharmaceuticals recently reported second quarter 2025 results, showing revenues of US$37.96 million, up sharply from US$3.5 million a year earlier, and a net loss of US$71.85 million, compared with US$68.06 million previously. Alongside this earnings release, the company announced that the FDA has granted Priority Review for Revuforj’s supplemental New Drug Application in relapsed or refractory mutant NPM1 acute myeloid leukemia, highlighting expanding opportunities in its targeted...